Report Overview

The Australian Hereditary Angioedema Therapeutics Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Hereditary Angioedema is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway. Usually, this swelling is not accompanied by itching, as it might be with an allergic reaction. Swelling of the gastrointestinal tract leads to cramping. Swelling of the airway may lead to obstruction, a potentially very serious complication.

Hereditary Angioedema is a rare disorder that affects males and females in equal numbers. Symptoms typically begin in early childhood.



Market Drivers

Lack of awareness about HAE is a major reason for misdiagnosis, which in turn, leads to inadequate treatment being provided to patients. Most patients with hereditary angioedema are misdiagnosed for conditions related to appendicitis, gastrointestinal disorders, and other non-allergic angioedema. Significant number of patients being misdiagnosed for the condition has generated a vast patient pool with substantial medical needs. This is likely to be a key driving factor for the market. Rising initiatives for improving awareness levels among the general population is another factor contributing to the growth of the market. Intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline are some more growth factors.

Major Types of Treatment of Hereditary Angioedema

Treatment for HAE includes on-demand and prophylaxis treatment. On-demand treatment accounted for the largest share in the market in 2020. Continued use of on-demand products for management of acute Hereditary Angioedema attacks is a high impact rendering driver for the Hereditary Angioedema Therapeutics market.